奈达铂、紫杉醇联合同期放疗治疗早中期宫颈癌的疗效

发布时间：2018-01-13 03:25

本文关键词：奈达铂、紫杉醇联合同期放疗治疗早中期宫颈癌的疗效　出处：《临床医药文献电子杂志》2016年57期 　论文类型：期刊论文

【摘要】：目的评估奈达铂、紫杉醇联合同期放疗治疗早中期宫颈癌的疗效。方法选取2014年6月~2016年4月我院收治的早中期宫颈癌患者50例作为研究对象,以不同治疗方法作依据分组:实验组25例,予以奈达铂、紫杉醇联合同期放疗治疗,参照组25例,予以放疗治疗,同时比对两组临床有效率、不良反应。结果予以不同药物医治后,对所选病例展开3~6个月随访,实验组25例有效率96.0%(24/25);参照组25例,有效率72.0%(18/25);且实验组1例(4.0%)发生不良反应,参照组5例(20.0%)发生不良反应,差异有统计学意义(P0.05)。结论在对早中期宫颈癌患者医治时,予以奈达铂、紫杉醇联合同期放疗治疗,可在改善医治有效率的基础上,防治不良反应发生。
[Abstract]:Objective to evaluate nedatin. The efficacy of paclitaxel combined with concurrent radiotherapy in the treatment of cervical cancer in early and middle stage. Methods 50 patients with cervical cancer in our hospital from June 2014 to April 2016 were selected as study subjects. According to different treatment methods, 25 patients in the experimental group were treated with neidplatin and paclitaxel combined with concurrent radiotherapy, 25 patients in the control group were treated with radiotherapy, and the clinical effective rate was compared between the two groups. Results after treatment with different drugs, the selected cases were followed up for 3 ~ 6 months. The effective rate of 25 cases in the experimental group was 96.0 / 25; There were 25 cases in the reference group, the effective rate was 72.0% and 18% 25%; Adverse reactions occurred in 1 case in the experimental group and 20.0% in the control group (P 0.05). Conclusion in the early and middle stage of cervical cancer treatment, there is a significant difference between the two groups. Nedaplatin and paclitaxel combined with concurrent radiotherapy can prevent and cure adverse reactions on the basis of improving the effective rate of treatment.
【作者单位】：南京鼓楼医院集团宿迁市人民医院妇科;
【分类号】：R737.33
【正文快照】： 为进一步评估奈达铂、紫杉醇联合同期放疗治疗早中期宫颈癌的疗效,此次筛选我院收治的早中期宫颈癌患者5 0例作研究对象,予以奈达铂、紫杉醇联合同期放疗治疗,现报道如下。1资料与方法1.1一般资料选取2014年6月~2016年4月我院收治的早中期宫颈癌患者50例作为研究对象,按照不同

【相似文献】